Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag for Thrombocytopenia in Cancer Patients with Liver Disease
NCT04437953Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of avatrombopag in Thrombocytopenia, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of patients who achieve platelet counts of ≥ 100,000/mcL at 3 weeks. Planned start May 2020; status: withdrawn.
02
Drugs
avatrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT04437953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04437953.